Genovefa Papanicolaou, MD, explains in which patient population is CMV most harmful.
Genovefa Papanicolaou, MD, Attending Physician, Infectious Diseases, Memorial Sloan Kettering Cancer Center, explains in which patient population is CMV most harmful.
Interview Transcript (slightly modified for readability)
“[Cytomegalovirus] can be particularly harmful in patients that have undergone bone marrow transplants.
Actually, CMV is the single most important viral infection [to watch for] after transplantation. Approximately 40% up to 70% of patients that are seropositive for CMV might [experience] CMV reactivation after transplant.”
DISCLOSURES: Genofeva Papanicolaou has received research funding from Merck and consultant and research funding from Astellas and Chimerix.
